- Home
- ALLR vs NXTC Comparison
ALLR vs NXTC Comparison
Compare ALLR & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- NXTC
- Stock Information
- Founded
- ALLR 2004
- NXTC 2015
- Country
- ALLR United States
- NXTC United States
- Employees
- ALLR N/A
- NXTC N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- NXTC Health Care
- Exchange
- ALLR Nasdaq
- NXTC Nasdaq
- Market Cap
- ALLR 15.8M
- NXTC 13.0M
- IPO Year
- ALLR N/A
- NXTC 2019
- Fundamental
- Price
- ALLR $1.52
- NXTC $5.67
- Analyst Decision
- ALLR Strong Buy
- NXTC Strong Buy
- Analyst Count
- ALLR 1
- NXTC 2
- Target Price
- ALLR $9.00
- NXTC $25.50
- AVG Volume (30 Days)
- ALLR 21.5M
- NXTC 14.1K
- Earning Date
- ALLR 11-13-2025
- NXTC 11-06-2025
- Dividend Yield
- ALLR N/A
- NXTC N/A
- EPS Growth
- ALLR N/A
- NXTC N/A
- EPS
- ALLR N/A
- NXTC N/A
- Revenue
- ALLR N/A
- NXTC N/A
- Revenue This Year
- ALLR N/A
- NXTC N/A
- Revenue Next Year
- ALLR N/A
- NXTC N/A
- P/E Ratio
- ALLR N/A
- NXTC N/A
- Revenue Growth
- ALLR N/A
- NXTC N/A
- 52 Week Low
- ALLR $0.61
- NXTC $2.69
- 52 Week High
- ALLR $3.71
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- ALLR 52.13
- NXTC 64.35
- Support Level
- ALLR N/A
- NXTC $5.19
- Resistance Level
- ALLR $1.92
- NXTC $5.15
- Average True Range (ATR)
- ALLR 0.19
- NXTC 0.27
- MACD
- ALLR -0.08
- NXTC 0.07
- Stochastic Oscillator
- ALLR 73.79
- NXTC 80.63
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.